Specialized Working Groups (SWGs)
In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs. This model is based on the nine sections of the EHA Roadmap for European Hematology Research.
The EHA-SWGs are supported by EHA through allocation of session slots in its Annual Congress program, the organization of dedicated scientific meetings and facilitation of guidelines production, amongst other activities. Moreover, new activities are being explored in response to innovation and to anticipate future developments and needs in hematology research.
If you want to know more about EHA-SWGs, click here
The European Hematology Association is involved, at different levels, with a number of European Networks.
EHA is one of the 52 partners of HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in Hematology), a European Network of Excellence for big data in hematology.
HARMONY, funded through the Innovative Medicines Initiative (IMI), captures, integrates, analyzes and seeks to harmonize Big Data on various hematological malignancies (HMs). Integrating disease information in a single big data platform will improve understanding of HMs and the quality of patient care.
The European Reference Networks (ERNs) were created under the EU directive on Cross-border Healthcare to improve the quality, safety and accessibility of treatments for complex or rare diseases by pooling knowledge and resources. Launched in early 2017, EuroBloodNet (European Reference Network for rare hematological diseases) was born from the joint efforts of EHA and the European Network for Rare Congenital Anemias (ENERCA).
The network brings together over 100 highly specialized hospital centers with expertise on malignant and non-malignant rare hematological diseases. Patient involvement and support for patient organizations is a key feature of EuroBloodNet.
The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.
The “European Network for Innovative Diagnosis and treatment of Chronic Neutropenias” (EuNet-INNOCHRON) is a new COST Action (CA18233), whose aim is to promote research in the field of Chronic Neutropenias (CNPs) through a wide network of researchers with special interest in CNPs.
EuNet-INNOCHRON will facilitate interactions and collaborations among top-level European experts and young investigators from different scientific areas, e.g. Clinical and Laboratory Hematology, Immunology, Genetics, Molecular Biology and Regenerative Medicine. The aim is better characterization, diagnosis and treatment of the underlying diseases.
If you want to know more about EuNet-INNOCHRON, click here
GAPP Joint Action
GAPP Joint Action is aiming at facilitating the development of a common and optimal approach to assess and authorize preparation processes in blood and tissues establishments (BEs and TEs), adapting requirements as prescribed by Article 29 of Directive 2002/98/EC and Article 28 of Directive 2004/23/EC .
GAPP will ensure that any possible advantage or outcome is taken into account from two ongoing Public Health Programme projects focused on tissues and cells (EuroGTP and ECCTR) incorporating a need for clinical follow-up data as part of a comprehensive process authorization.
GAPP durable output is that a knowledge sharing platform on PPAs will be developed and fed in order to facilitate sharing of information among European Union, Competent Authorities and a number of CA inspectors will be trained specifically to assess and authorize preparation processes of tissues, cells, reproductive cells and blood products.
PROFILE Innovative Training Network
EHA was a partner in the PROFILE project, which ran from 2016 to 2021. PROFILE was an EU (Horizon 2020) funded 'Innovative Training Network' geared towards the stratification of patients with the rare autoimmune disorder Thrombotic Thrombocytopenic Purpura (TTP).
The joint doctoral training (European Industrial Doctorate) provided by the academic and corporate partners in PROFILE allows PhD students to develop skills inside and outside academia that respond to public and private sector needs.
EHA has supported the work of the EUnetHTA consortium, which has piloted collaboration between EU Member States on Health Technology Assessment (HTA), by identifying and facilitating the involvement of leading experts in hematology in joint clinical assessments. The collaboration with EUnetHTA is an example of how EHA, as part of its European Affairs portfolio, works to ensure that the expert views of hematologists are taken into account in all relevant EU decision-making and regulatory processes, such as the evaluation of existing legislation (European Commission) and the authorization of new drugs for the EU market (European Medicines Agency).
EHA is actively encouraging the emergence of an EU framework for joint horizon scanning, scientific consultations and clinical assessments under the HTA Regulation (adopted December 2021) as part of its broader engagement with EU authorities and stakeholders aimed at improving access to innovative treatments.